Wuhan Scientists Discover ‘NeoCov,’ A New Coronavirus Strain with a High Death Rate of “1 in 3”

Kathleen Kinder
Kathleen Kinder

Updated · Jan 31, 2022

SHARE:

News.Market.us is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more.
close
Advertiser Disclosure

At Market.us News, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us News. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

The year is 2020. Scientists in China have finally detected the beginnings of NeoCov, the new bacterial virus that will devastate human populations. The scientists have been able to isolate a small sample of the bacteria and have figured out what type it is. They also believe they know how it was created and how long it has been around.

Wuhan scientists have detected a new global pandemic, NeoCov. The new virus was found to be able to jump from one host species to another. This is the first time that the virus had successfully jumped from one animal species to another. One of the main symptoms of this pandemic is that it makes its host susceptible to any kind of physical injury. It has been shown that this virus can infect humans just as easily as other animals.

On March 14th, Wuhan scientists had detected NeoCov in the soil of their laboratory. NeoCov is a deadly virus that causes the human body to quickly deteriorate. It is believed to be created by Dr. Annette Davis, who was recently found dead in her lab after its security camera went out of service. She was also the head scientist at the lab.

The threat of new coronavirus variants is looming large as the world struggles to deal with the Omicron variant’s recent spike in coronavirus cases. Scientists in Wuhan, China, where the virus was first discovered, have warned about a new COVID-19 variant being called “NeoCov”. Multiple reports have indicated that NeoCov was discovered in South Africa and is considered to be a more dangerous variant of the virus.

NeoCov isn’t new. According to reports from Sputnik ( via IndiaTody), Russia’s news agency, NeoCov may be linked to MERS–CoV, a respiratory illness that caused an epidemic in 2015 and 2012 in some Middle Eastern countries. This strain was found in South Africa’s bat population and has not been seen spreading to other animals. This information was published by bioRxiv.org. It is important to note that it has not been peer-reviewed. The report warned that NeoCov’s mortality rate is high, and “one-third of people” could die.

Researchers at Wuhan University and the Chinese Academy of Sciences’ Institute of Biophysics believe that the virus is only one mutation away from infecting people. NeoCov is also believed to be at high risk for death and infection.

According to reports from the Russian news portal TASS: “Experts at the Vector research center are aware of data that Chinese researchers have obtained concerning the NeoCov coronavirus.” It’s not about the possibility of a new coronavirus that could actively spread among humans i>

Although NeoCov is currently under investigation, it has not been declared a variant of concern to the World Health Organisation (WHO). However, the WHO is aware of NeoCov. According to TASS, the WHO said “Whether or not the virus detected during the study will pose an imminent risk for humans will require additional study.”

There are no known cases of this virus strain at the moment.

SHARE:
Kathleen Kinder

Kathleen Kinder

With over 4 years of experience in the research industry, Kathleen is generally engrossed in market consulting projects, catering primarily to domains such as ICT, Health & Pharma, and packaging. She is highly proficient in managing both B2C and B2B projects, with an emphasis on consumer preference analysis, key executive interviews, etc. When Kathleen isn’t deconstructing market performance trajectories, she can be found hanging out with her pet cat ‘Sniffles’.